In devising the new 2018 breast cancer guidelines in Japan, we conducted a systematic review and meta-analyses to investigate what treatment options are optimal in the first-line therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Here, ERBB2 is linked to breast cancer.